Boehringer Ingelheim Group of companies
Financial Highlights 2016
Financial Highlights 2016
| Boehringer Ingelheim group of companies | 2016 | 2015 | Change |
|---|---|---|---|
| Net sales | 15,850 | 14,798 | 7% |
| Net sales by region | |||
| Europe | 32% | 28% | |
| Americas | 41% | 47% | |
| Asia, Australia, Africa | 27% | 25% | |
| by business | |||
| Prescription Medicines | 76% | 76% | |
| Consumer Health Care | 10% | 10% | |
| Animal Health | 9% | 9% | |
| Biopharmaceuticals | 4% | 4% | |
| Industrial Customers and other sales | 1% | 1% | |
| Research and Development | 3,112 | 3,004 | +4% |
| Personnel costs | 4,570 | 4,518 | +1% |
| Average number of employees | 45,692 | 47,501 | -4% |
| Operating income | 2,872 | 2,269 | +27% |
| Operating income as % of net sales | 18.1% | 15.3% | |
| Income after taxes | 1,853 | 1,577 | +18% |
| Income after taxes as % of net sales | 11.7% | 10.7% | |
| Shareholders' equity | 11,327 | 9,603 | +18% |
| Return on shareholders' equity | 19.3% | 19.4% | |
| Cash flow | 2,484 | 2,605 | -5% |
| Investments in tangible assets | 645 | 591 | +9% |
| Depreciation of tangible assets | 516 | 475 | +9% |